Survey gauges knowledge and capacity of primary care providers in screening for type 1 diabetes, highlighting significant gaps.
Type 1 diabetes has been redefined to include pre-symptomatic stages prior to clinical disease.¹ Screening for islet autoantibodies is recommended in those with a known family history or elevated genetic risk to enable access to interventions and reduce diabetic ketoacidosis (DKA) at diagnosis.² For those with positive antibodies, consensus guidance recommends monitoring for dysglycemia at regular intervals based on age and antibody number.³ Screening is generally supported by pediatric and adult endocrinologists, though chronically understaffed clinics may limit implementation.⁴ The guidance advocates that primary care providers (PCPs) participate in screening and monitoring.³ Though PCPs have identified priorities for type 1 diabetes screening tests,⁵ little is known about their understanding and capacity to engage in screening and monitoring, an essential first step prior to implementing widescale programs.
No takes yet. Share an insight, caveat, or question.
March et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: